Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Indapamide is a prescription oral antihypertensive and diuretic. It is chemically distinct from thiazide diuretics but has similar diuretic actions. Current tablets include 1.25 mg and 2.5 mg strengths.
read more about indapamide ...Indapamide increases urinary sodium and water excretion and reduces peripheral vascular resistance. Its diuretic and vascular actions contribute to blood pressure reduction. Potassium loss increases as the dose rises.
Indapamide is indicated for hypertension as monotherapy or with other antihypertensive medicines. It is also indicated for salt and fluid retention associated with congestive heart failure. Anuria and hypersensitivity to indapamide or other sulfonamide-derived drugs are contraindications.
Hypertension treatment starts at 1.25 mg once daily in the morning. The dose can increase to 2.5 mg after four weeks and then to 5 mg after another four weeks if needed. Heart failure edema starts at 2.5 mg each morning and can increase to 5 mg after one week.
Indapamide can cause severe low sodium and low potassium, particularly at higher doses. Other concerns include fluid and electrolyte imbalance, increased uric acid, changes in blood glucose, kidney dysfunction, photosensitivity, blood-cell disorders, and acute myopia or angle-closure glaucoma. Serum electrolytes are checked periodically during treatment.
Indapamide treats hypertension and salt and fluid retention associated with congestive heart failure.
The adult starting dose is 1.25 mg once daily in the morning.
The adult starting dose is 2.5 mg once daily in the morning.
Yes. Hyponatremia and hypokalemia are recognized risks, and electrolyte monitoring is part of treatment.
Clinical Efficacy and Safety of Lower-Dose Indapamide Therapy in the Treatment of Patients With Mild to Moderate Hypertension. https://pubmed.ncbi.nlm.nih.gov/11835068/. Date Accessed October 2, 2026.
DailyMed - INDAPAMIDE tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59cd3331-7afe-432a-8b50-39533fd5f392. Date Accessed October 2, 2026.
Double-Blind Comparison of Indapamide With a Placebo in Hypertensive Patients Treated by Practicing Physicians. https://pubmed.ncbi.nlm.nih.gov/3899418/. Date Accessed October 2, 2026.
Indapamide - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a684062.html. Date Accessed October 2, 2026.
Indapamide - Medical Subject Headings. https://www.ncbi.nlm.nih.gov/mesh/68007190. Date Accessed October 2, 2026.